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Summary. High plasma levels of yon Willebrand factor, an in- 
dicator of endothelial cell dysfunction, have been reported in 
both diabetic retinopathy and nephropathy. It is unclear, 
however, whether yon Willebrand factor is related to diabetic 
retinopathy inthe absence of diabetic nephropathy. The rela- 
tionship between retinal status and plasma von Willebrand 
factor concentration was investigated in a cohort of 17 pa- 
tients with Type 1 (insulin-dependent) diabetes mellitus who 
were followed-up for a median of 42 months. The patients 
were examined three times. They were selected for having 
had normal urinary albumin excretion and no evidence of re- 
tinopathy (on fundoscopy) at the first and second exami- 
nation. They were then divided into two groups, according to 
absence (Group A; n = 9) or presence (Group B; n = 8) of re- 
tinopathy on fundoscopy or fluorescein angiography at the 
third examination. Urinary albumin excretion remained nor- 
mal in all patients. Plasma von Willebrand factor levels were 
similar in both groups: (median) 128 vs 123 %, 164 vs 132 % 
and 159 vs 130 % (first, second and third examination, respec- 
tively). Median changes in plasma yon Willebrand factor 
were also similar: + 7 vs + 9 % and + 5 vs + 1% (first-second 
and second-third examination). Patients in whom the plasma 
yon Willebrand factor concentration i creased had higher 
systolic blood pressure at the third examination (150 + 30 vs 
130 + 12 mmHg,p --- 0.02) when compared to those in whom 
plasma von Willebrand factor did not increase, but were of 
similar age and had similar diabetes duration, retinal status, 
diastolic blood pressure, glycated haemoglobin and serum 
cholesterol concentration. These data do not support the hy- 
pothesis that increases in plasma yon Willebrand factor con- 
centration reflect retinal endothelial injury in Type i diabetic 
patients with normal urinary albumin excretion. In these pa- 
tients, high or increasing plasma yon Willebrand factor levels 
may be related to systolic blood pressure. 
Key words: von Willebrand factor, endothelial function, 
diabetic retinopathy, blood pressure. 
In the treatment of Type i (insulin-dependent) diabetes 
mellitus, prevention of micro- and macroangiopathic com- 
plications is an important, but as yet elusive, goal. Recent 
epidemiological data suggest that patients with diabetic ne- 
phropathy often suffer from clinically important retino- 
pathy and macroangiopathy [1-5]. The identification of 
microalbuminuria, . e. a slightly elevated urinary albumin 
excretion rate, as a strong predictor of clinical diabetic ne- 
phropathy [6, 7] has allowed clinicians to identify agroup of 
patients at high risk of developing severe complications of
diabetes thereby targeting these patients for intensified 
treatment. It has become clear, however, that microalbu- 
minuria constitutes incipient diabetic nephropathy [7]. 
Therefore, it may be useful to define risk indicators of 
diabetic omplication development a an earlier stage, i.e. 
when urinary albumin excretion isnormal. 
Although diabetic nephropathy appears linked to 
severe retinopathy [5], hypertension [5] and cardiovascu- 
lar disease [3, 4], the nature of this linkage is not clear. It 
has been suggested that dysfunction of vascular endothe- 
lium may represent the pathophysiological b sis for these 
epidemiological observations [8, 9], being involved in the 
development ofproteinuria [10], retinopathy [11], hyper- 
tension [12] and atherosclerosis [13]. Vascular endothe- 
lium is intimately involved in the regulation of various 
processes, e.g., haemostasis, fibrinolysis, vasomotor con- 
trol and vascular permeability, all of which may be rele- 
vant to the pathogenesis of diabetic omplications. There- 
fore, markers of endothelial dysfunction are candidate 
risk indicators for the development ofsuch complications. 
yon Willebrand factor (vWF), a glycoprotein mportant in 
primary haemostasis and synthesised mainly by endothe- 
lial cells, may serve as such a marker [8, 14, 15], high plas- 
ma levels indicating endothelial injury. In support of this 
hypothesis, the development ofincipient diabetic nephro- 
pathy was shown to be paralleled by increases in plasma 
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vWF concentrat ion [16]. It is unclear, however,  whether  
deve lopment  of diabet ic re t inopathy  issimilarly accompa- 
nied by increases in p lasma vWF. To invest igate this, we 
studied the re lat ionship between ret inal  status and p lasma 
vWF level in pat ients  with Type i d iabetes and normal  uri- 
nary a lbumin excretion. 
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The sensitivity of this method is 0.4 rag/1. On the basis of the mean 
urinary albumin excretion rate in at least three consecutive 4-h 
morning urine collections [6, 7], patients were classified as having 
normal ( < 15 gg/min [19]) or increased urinary albumin excretion. 
Ophthalmological studies 
Subjects and methods 
Cohort study 
As part of a prospective study attempting todefine the relationship 
between development of complications of diabetes and markers of 
endothelial dysfunction, 65 patients with Type 1 diabetes (fasting C- 
peptide level ess than 0.01 nmol/1) were selected, as previously de- 
scribed [16]. Informed consent was given for the following studies by 
all patients. Clinical and laboratory data, as detailed below, were ob- 
tained at three time points: between June, 1985, and August, 1989 
('first examination'), between June, 1987, and March, 1990 ('second 
examination') and again between January and April, 1990 ('third 
examination'). The first and second examination were completed in
59 patients, 21 of whom had an abnormal urinary albumin excretion 
rate. Patients were invited for the third examination when, at the sec- 
ond examination, they had had normal urinary albumin excretion, 
no diabetic retinopathy on ophthalmoscopy, fair (HbAlc < 8.5 %) 
glycaemic ontrol and used no medication other than insulin. Pa- 
tients in poor glycaemic control were excluded to avoid a possible 
confounding effect on plasma levels of vWF [17]. 
Clinical and laboratory studies [16] 
At each examination, we recorded age, diabetes duration, body mass 
index, blood pressure, insulin dose, current smoking habits and cur- 
rent medication. Blood pressure (diastolic phase V) was measured 
twice after 15 min of supine rest using a standard sphygmoma- 
nometer with an appropriately sized cuff. In the six weeks prior to 
each examination, allpatients collected three or more urine samples 
for determination f urinary albumin. (Data were collected without 
knowledge of the patient's retinal status or plasma vWF level.) After 
an overnight fast, blood was drawn from an antecubital vein for 
measurement of glucose, vWF antigen and glycated haemoglobin. 
Glucose was determined using a glucose oxidase method, vWF 
antigen was measured by immunoelectrophoresis [18], using a poly- 
clonal antibody. The intra- and interassay variation of this method 
are 4.1 and 8.7 %, respectively. Care was taken to avoid increases in
vWF associated with hypoglycaemia, exercise and venous occlusion, 
as previously described [16]. In our experience, the within-person 
day-to-day variability of plasma vWF antigen concentration is thus 
reduced to approximately 10% (unpublished observation). Levels 
of and changes in vWF are expressed as percentages of normal 
pooled plasma, the activity of which is defined as 100 % (normal 
range in our laboratory, 50-150 %). An increase in plasma concen- 
tration of vWF is defined as a change of more than + 10 % (in view of 
the estimated within-person day-to-day variability). Glycated 
haemoglobin was measured with a spectrophotometric assay using 
reagents obtained from Bi0-Rad (Richmond, Va., USA). Two assays 
were used, for HbAz and HbAlc, respectively. According to the 
manufacturer and in agreement with our own observations, glycated 
haemoglobin measured by the latter assay is comparable to75-80 % 
of values obtained by the former method. Therefore, all measure- 
ments are reported as glycated haemoglobin, using 0.775 and 1.0 as 
converting factors. Thus, the normal range in our laboratory for gly- 
cared haemoglobin s 3.56.5 %. Serum cholesterol concentration 
was determined with an enzymatic technique (Boehringer Mann- 
heim, Mannheim, FRG). Urinary albumin concentration was deter- 
mined by radioimmunoassay (Pharmacia AB, Uppsala, Sweden). 
At the first and second examination, the ocular fundus was exam- 
ined by an ophthalmologist af er dilatation of the pupils and classi- 
fied as normal (less than 3 microaneurysms), background retino- 
pathy or proliferative retinopathy. At the third examination 
ophthalmoscopy was repeated by two ophthalmologists. In addition, 
fluorescein angiograms were obtained after intravenous injection of 
5 ml of a 10% solution of sodium fluorescein and assessed by two 
ophthalmologists. All ophthalmological studies were done without 
knowledge of the patients' vWF plasma levels. 
Statistical nalysis 
To assess the relationship between retinal status and plasma vWF 
level, the patients were divided into two groups according to the ab- 
sence (Group A) or the presence (Group B) of retinopathy (at the 
third examination) and compared with regard to vWF levels. The 
statistical power to detect differences between the groups with 
c~ = 0.05 depends on the number of patients in each group, the level 
of difference to be detected and the variance in the variable 
measured. For our investigation, the power to detect a 50% dif- 
ference [11] in plasma vWF concentration between the groups was 
50 %. The power to detect a 15 % difference in changes in plasma 
vWF concentration, however, was 96 % between the second and 
third examination. Thus, the overall power to detect a relationship 
between retinal status and plasma vWF concentration appears ade- 
quate. 
To assess the relationship between endothelial dysfunction (as 
reflected by plasma vWF levels) and clinical data, the patients were 
divided into two groups according to the absence (Group 1) or the 
presence (Group 2) of an increase in plasma vWF levels between the 
first and second examination and compared with regard to clinical 
data. We were particularly interested in the relation between vWF 
and other possible determinants of endothelial injury (age, diabetes 
duration, glycated haemoglobin, smoking habits, serum cholesterol 
and blood pressure). 
Standard parametric and non-parametric statistical testing was 
used as appropriate. All testing was two-sided, p values < 0.05 were 
considered statistically significant. 
Results 
From the original cohort,  all 17 patients who were el igible 
at the second examinat ion agreed to part ic ipate in the 
third. Compl iance with the study protocol  [16] was excel- 
lent. There were only two smokers  among the patients; 
this factor was, therefore,  omitted from further analysis. 
A t  the t ime of the third examinat ion,  none of the pat ients 
had clinical evidence of macrovascular  compl icat ions or 
used any medicat ion other  than insulin. A l l  had normal  
ur inary a lbumin excretion. B lood glucose levels at the 
t ime of b lood sampl ing for vWF measurements  var ied be- 
tween 3.6 and 15.7 mmol/1. Ret ina l  abnormal i t ies were 
observed on fundoscopy in six of 17 patients. These ab- 
normal i t ies were general ly  mild and consisted of micro-  
aneurysms and, in five patients, small haemorrhages.  
F luorescein angiograms, obta ined in 16 of 17 patients,  
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Table 1. Clinical and laboratory data of a cohort of 17 patients with 
Type i (insulin-dependent) diabetes mellitus examined three times, 
according to the presence of retinopathy" 
Group A Group B 
Retinopathy Retinopathy 
absent present 
9 (4/5) 8 (4/4) n (men/women) 
Follow-up (months) 
lst-2nd examination 25 + 12 
2nd-3rd examination 15 +_ 5 
Age (years) 49 + 18 
Diabetes duration (years) 8 (2-35) 
Glycated haemoglobin (%) 
1st examination 7.7 • 0.9 
2nd examination 7.1 2 0.8 
3rd examination 6.8 + 0.7 




Serum cholesterol (mmol/1) 
1st examination 6.3 + 0.8 
2nd examination 6.4 + 0.7 
3rd examination 6.3 + 0.8 






30 + 12 
14• 





151/88 •26/7 126/79 __+ 15/11 ~ 
141/84 + 22/7 130/81 + 16/9 




128 (98-210) 123 (87-129) 
164 (69-206) 132 (92-274) 
159 (82-210) 130 (90-270) 
+ 7 (-33 to + 102) + 9 (-18 to + 145) 
+ 5 (~5 to + 13) + 1 (-8 to + 20) 
Data are given as mean • SD or as median (range), unless otherwise 
indicated, a as determined atthe third examination (see Subjects 
and methods); bp = 0.02; c p = 0.03 for difference in systolic blood 
pressure between groups A and B 
were abnormal in seven patients. In the patient in whom 
angiography was not performed, fundoscopy had shown 
several small retinal haemorrhages (for the statistical ana- 
lysis, angiography in this patient was considered abnor- 
mal). Retinal abnormalities observed on angiography 
were: dilated perimacular capillaries and microaneurysms 
in all patients and small retinal haemorrhages in four pa- 
tients. 
Retinal status and plasma vWF level 
vWF and presence of retinopathy: At the third exami- 
nation, retinopathy was absent (on both fundoscopy and 
angiography) in nine patients (Group A) and present in 
eight (Group B). Table I shows clinical and laboratory 
data. The groups were comparable with regard to sex 
ratio, follow-up duration, age, glycated haemoglobin, 
serum cholesterol concentration and diastolic blood 
pressure. In Group B, systolic blood pressure was lower at 
the first examination (151+26 vs 126 +15 mmHg, 
p - 0.03), but this difference was less clear (and non-sig- 
nificant) at the subsequent examinations. Diabetes dura- 
tion was longer in Group B (median 8 vs 15 years, 
p =0.02). No differences were observed between the 
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groups with regard to absolute levels of or changes in plas- 
ma vWF at any of the three examinations (Table 1). 
vWF and development of retinopathy: Angiograms 
were not obtained at the first two examinations. Develop- 
ment of retinopathy can therefore be judged only on the 
basis of the results of fundoscopy. At the third exami- 
nation, fundoscopic evidence of retinopathy was present 
(i. e. had developed) in six patients and absent in eleven. 
The plasma levels of vWF were not significantly different 
between these groups, nor were changes in the plasma 
vWF levels, vWF levels (median and range) were 119 
(87-129) and 125 (98-210) % at the first examination, 132 
(92-274) and 164 (69-206)% at the second examination 
and 130 (90-270) and 159 (82-210) % at the third exami- 
nation, respectively. Changes in vWF were + 9 ( + 5 to 
+ 145) and + 7 ( - 35 to + 102) % between the first and 
second examination and - 3 ( - 8 to + 20) and + 5 ( - 6 to 
+ 18) % between the second and third examination. 
Changes in plasma vWF level and clinical characteristics 
Between the first and second examination, plasma vWF 
levels remained stable or decreased in 10 patients (from 
[median] 123 to 121%; Group 1) and increased (from 
[median] 125 to 200 %) in seven (Group 2). Table 2 shows 
clinical and laboratory data of these two groups. The 
groups were not significantly different regarding sex ratio, 
follow-up duration, age, diabetes duration, glycated 
haemoglobin, serum cholesterol concentration and uri- 
nary albumin excretion. Retinal status, too, was similar in 
both groups. Abnormalities on fundoscopy were present 
in four of ten patients in Group i and in two of seven pa- 
tients in Group 2. The severity of the retinopathy was not 
different between the groups. Angiography was abnormal 
in four of nine patients in Group i and in three of seven 
patients in Group 2, and again the abnormalities observed 
were of similar severity. Systolic blood pressure tended to 
be higher in Group 2, a difference that became significant 
at the third examination (133 +_ 14 vs 149 + 34 [p = 0.21], 
128+13 vs 146+23 [p=0.05] and 132+_11 vs 
149 + 17 mmHg [p = 0.02], respectively; Table 2). Dias- 
tolic pressures, however, were not significantly different. 
Correlation analysis disclosed no significant correlation 
between absolute levels of, or changes in, blood pressure 
and plasma vWF. Finally, the difference in vWF level at 
the third examination (median, 118 vs 205 %) was highly 
significant (p =0.001), indicating that intra-individual 
changes in plasma vWF between the second and third 
examination were generally small and not different be- 
tween the groups (median, +4 vs +5%,  p =0.41; 
Table 2). 
Discussion 
In patients with Type 1 diabetes and normal urinary al- 
bumin excretion, retinal status and plasma vWF concen- 
tration do not appear elated, nor do changes in plasma 
vWF level predict he presence or development of early 
diabetic retinopathy. 
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Table 2. Clinical and laboratory data of a cohort of 17 patients with 
Type 1 (insulin-dependent) diabetes mellitus examined three times, 
according to an increase in plasma von Willebrand factor level s
Group 1 Group 2 
No increase in Increase in 
yon Willebrand von Willebrand 
factor factor 
n (men/women) 10 (5/5) 7 (3/4) 
Follow-up (months) 
lst-2nd examination 24 + 11 32 + 12 
2nd-3rd examination 14 • 4 15 • 3 
Age (years) 46 + 12 47 + 19 
Diabetes duration (years) 13 (11-47) 12 (2-35) 
Glycated haemoglobin (%) 
1st examination 8.1 i 1.0 8.2 • 1.3 
2nd examination 6.9 • 0.8 6.8 • 1.1 
3rd examination 6.8 • 0.8 6.7 • 0.9 
Blood pressure (mmHg) 
1st examination 133/84 • 14/6 149/84 • 34/14 
2nd examination 128/80 • 13/4 146/86 -+23/10 b
3rd examination 130/84 • 12/4 150/86 + 30/8 c
Serum cholesterol (mmol/1) 
1st examination 6.1 • 0.8 6.1 _+ 0.8 
2nd examination 6.2 • 0.6 6.2 • 0.7 
3rd examination 6.1 • 0.8 6.0 • 0.7 
von Willebrand factor (%) 
1st examination 123 (87-210) 125 (98-161) 
2nd examination 120 (6%186) 200 (164-274) d 
3rd examination 118 (82-190) 205 (159-270) e 
change lst-2nd -1 (-33 to + 9) 59 (39 to 145) d
+ 5 @6 to + 20) change 2nd-3rd + 4 (-8 to + 13) 
Urinary albumin excretion (gg/min) 
1st examination 6.1 (2.4-12.9) 6.4 (3.1-14.2) 
2nd examination 7.4 (3.6-14.2) 7.2 (3.9-13.6) 
3rd examination 6.8 (3.%14.3) 6.9 (4.2-13.9) 
Fundoscopy f (No. [%] normal) 6 (60%) 5 (71%) 
Fluorescein angiography f 
(No. [% ] normal) 5 (55 %) 4 (57 %) 
Data are given as mean + SD or as median (range), unless otherwise 
indicated, abetween the first and second examination (see Subjects 
and methods); bp = 0.05 and Cp = 0.02 for difference in systolic 
bloodpressure b tween groups i and 2; d not tested; ~p = 0.001; e at 
the third examination (see Subjects and methods) 
It has repeatedly been shown that measures of endo- 
thelial function tend to be abnormal in patients uffering 
from diabetic microangiopathy [8, 9, 11, 15, 16, 20, 21]. 
The plasma level of vWF is thought o reflect endothelial 
function [14], and, not surprisingly, the plasma vWF level 
is often reported as elevated in patients with diabetes, es- 
pecially when microangiopathy is present [8]. It is not 
clear, however, whether diabetic retinopathy or nephro- 
pathy is the more important determinant of high vWF le- 
vels in these patients. In earlier studies [111 microalbu- 
minuria (i. e., incipient diabetic nephropathy as defined 
between 1982-1984 [6, 7]) was not excluded and may have 
confounded the results. In a cross-sectional study address- 
ing this issue, Jensen found elevated vWF levels in pa- 
tients with microalbuminuria, but no independent rela- 
tion of vWF with retinopathy as determined by 
fundoscopy [15]. His conclusions are supported by the 
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present study, which employed both fundoscopy and the 
more sensitive fluorescein angiography in patients in 
whom urinary albumin excretion was normal. Therefore, 
it appears that diabetic nephropathy, and not retinopathy, 
is the most important determinant of high vWF levels 
[15, 16]. This conclusion is consistent with epidemiologi- 
cal data showing that patients with diabetic nephropathy 
often have hypertension and cardiovascular disease [2-5], 
conditions that may be pathogenetically related to endo- 
thelial dysfunction [12, 13]. In fact, systolic blood pressure 
was significantly higher in the present study in those pa- 
tients in whom plasma levels of vWF increased. These 
considerations do not imply that endothelial dysfunction 
is not important in the pathogenesis of diabetic retino- 
pathy; a large body of evidence to the contrary exists [22]. 
High vWF levels, however, may not directly reflect dys- 
function of retinal endothelium, as opposed to endothe- 
lium elsewhere in the body. Moreover, as retinal blood 
flow represents only a small part of total body blood flow, 
it appears a priori unlikely that high systemic vWF levels 
should be determined by increased production by retinal 
endothelium. Note, however, that the selection criteria 
employed here necessarily restrict the study's relevance to 
a specific ategory of patients, i. e. well-controlled patients 
with early retinopathy; no conclusions can be drawn with 
regard to more advanced stages of retinal disease. 
How, then, may the changes in plasma vWF levels ob- 
served in our patients, who had normal urinary albumin 
excretion, be explained? vWF levels may be influenced by 
age [23] and, possibly, by glycaemic ontrol [16, 17, 24], 
but, as these factors were similar in patients with and with- 
out increases in plasma vWF, they are an unlikely explana- 
tion for the differences invWF level changes observed. As 
diabetic nephropathy is associated with both high vWF 
concentrations and a high incidence of cardiovascular dis- 
ease [3-5, 15, 16], and as atherosclerosis in non-diabetic 
patients is also associated with high vWF levels [25, 26], 
we propose that diabetic patients with normal urinary al- 
bumin excretion and high or increasing vWF levels have 
clinically silent endothelial dysfunction, which may indi- 
cate an increased risk of developing nephropathy and car- 
diovascular disease. In this regard, the higher systolic 
blood pressures observed in patients with increases in 
plasma vWF concentration may indicate increased arte- 
rial stiffness, which may be due to atherosclerosis [27]. Al- 
ternatively, higher blood pressure may cause endothelial 
injury. Obviously, further prospective studies are needed 
to test these hypotheses. 
In conclusion, we found no relationship between 
changes in plasma vWF level (as an indicator of endothe- 
lial function) and retinal status in patients with Type 1 
diabetes and normal urinary albumin excretion. Thus, in- 
creases in plasma vWF concentration, if indeed reflecting 
endothelial dysfunction, are probably not influenced by 
early retinal endothelial damage. Increases in the plasma 
vWF level were found to be associated with higher systolic 
blood pressures. As a role for endothelial dysfunction in 
the pathogenesis of vascular complications ofdiabetes ap- 
pears pathophysiologically p ausible, measuring markers 
of endothelial dysfunction may be clinically relevant. 
vWF may be one such marker; presence [15] and develop- 
c. D. A. Stehouwer et al.: von Willebrand factor and early retinopathy 
ment  [16] of microa lbuminur ia  are associated with in- 
creases in the p lasma level of vWE Further  studies are 
now warranted to investigate whether  high or increasing 
vWF levels precede and predispose to the deve lopment  of
microalbuminur ia.  
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